{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-067471","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.005417+00:00","generated_at":"2026-06-04T19:43:02.028842+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Amylyx appoints Dr. Bernhardt Zeiher to board, fills Class I director vacancy","bullets":["Appointed March 14, 2024 as Class I director; term expires at 2025 annual meeting.","Also named to Nominating and Corporate Governance Committee, replacing Paul Fonteyne.","Zeiher was Chief Medical Officer at Astellas Pharma from 2018-2022; joined Entrada Therapeutics board in 2023.","Receives initial option grant (lesser of $570K value or 50K shares); 1/3 vests at one year, remainder over two years.","Annual retainer of $45,000 plus $5,000 for Nominating Committee service; eligible for annual option grants."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-067471","json":"https://secwatch.observer/filing/0001193125-24-067471.json","markdown":"https://secwatch.observer/filing/0001193125-24-067471.md","text":"https://secwatch.observer/filing/0001193125-24-067471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/0001193125-24-067471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/d789002d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:43:02.028842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a5a337ead","claim":"Bernhardt Zeiher was appointed as Class I Director at Amylyx Pharmaceuticals, Inc..","evidence_excerpt":"On March 14, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Amylyx Pharmaceuticals, Inc. (the “Company”) appointed Bernhardt Zeiher, MD, FCCP, FACP to fill a vacancy on the Board as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312524067471/0001193125-24-067471-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}